Fundamental Analysis of PHARNEXT SA(EPA:ALPHA) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ALPHA. ALPHA was compared to 73 industry peers in the Biotechnology industry. ALPHA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ALPHA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALPHA had negative earnings in the past year.

ALPHA had a negative operating cash flow in the past year.

ALPHA had negative earnings in each of the past 5 years.

ALPHA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -627.44%, ALPHA is not doing good in the industry: 98.59% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-627.44%
ROE	N/A
ROIC	N/A

ROA(3y)-259.01%

ROA(5y)-189.28%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALPHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALPHA remains at a similar level compared to 1 year ago.

Compared to 5 years ago, ALPHA has less shares outstanding

ALPHA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -31.74, we must say that ALPHA is in the distress zone and has some risk of bankruptcy.

ALPHA has a worse Altman-Z score (-31.74) than 94.37% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-31.74

ROIC/WACCN/A

WACC6.43%

2.3 Liquidity

ALPHA has a Current Ratio of 0.37. This is a bad value and indicates that ALPHA is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.37, ALPHA is doing worse than 92.96% of the companies in the same industry.

A Quick Ratio of 0.37 indicates that ALPHA may have some problems paying its short term obligations.

With a Quick ratio value of 0.37, ALPHA is not doing good in the industry: 92.96% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.37
Quick Ratio	0.37

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.99% over the past year.

The Revenue for ALPHA has decreased by -99.34% in the past year. This is quite bad

The Revenue for ALPHA have been decreasing by -86.96% on average. This is quite bad

EPS 1Y (TTM)99.99%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%100%

Revenue 1Y (TTM)-99.34%

Revenue growth 3Y-86.96%

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 41.39% on average over the next years. This is a very strong growth

ALPHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 93.12% yearly.

EPS Next Y99.81%

EPS Next 2Y41.39%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-22.9%

Revenue Next 2Y93.12%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALPHA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALPHA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ALPHA's earnings are expected to grow with 41.39% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.39%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALPHA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PHARNEXT SA

EPA:ALPHA (8/26/2024, 7:00:00 PM)

0.0002

+0 (+100%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.19K

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-627.44%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.37
Quick Ratio	0.37
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)99.99%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y99.81%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-99.34%

Revenue growth 3Y-86.96%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PHARNEXT SA (ALPHA.PA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens